Section Arrow
ZYME.NASDAQ
- Zymeworks
Quotes are at least 15-min delayed:2024/12/25 01:00 EST
Last
 14.14
-0.14 (-0.98%)
Day High 
14.35 
Prev. Close
14.28 
1-M High
14.77 
Volume 
208.99K 
Bid
13.8
Ask
14.15
Day Low
13.845 
Open
14.3 
1-M Low
12.43 
Market Cap 
983.57M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 13.32 
20-SMA 13.72 
50-SMA 14.19 
52-W High 17.7 
52-W Low 7.97 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.49/-2.05
Enterprise Value
1.01B
Balance Sheet
Book Value Per Share
5.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
76.01M
Operating Revenue Per Share
6.70
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed:2024/12/25 01:00 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.